Buddha Dawn (Medicine) co-authored an article, “A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-derived Mesenchymal Stromal Cells for the Treatment of de novo High-risk or Steroid-refractory Acute Graft Versus Host Disease,” in Stem Cell Reviews and Reports. This study evaluated the safety of Wharton’s jelly MSCs in 10 patients with severe acute GvHD, a condition that is often lethal. The results showed that cell therapy was safe, and resulted in clinical improvement in approximately 70 percent of patients.
